452 related articles for article (PubMed ID: 29216340)
1. Incorporating blood-based liquid biopsy information into cancer staging: time for a TNMB system?
Yang M; Forbes ME; Bitting RL; O'Neill SS; Chou PC; Topaloglu U; Miller LD; Hawkins GA; Grant SC; DeYoung BR; Petty WJ; Chen K; Pasche BC; Zhang W
Ann Oncol; 2018 Feb; 29(2):311-323. PubMed ID: 29216340
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
Cheng F; Su L; Qian C
Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
[TBL] [Abstract][Full Text] [Related]
3. A New Horizon in Cancer Care: Liquid Biopsy.
Copur M
Oncology (Williston Park); 2021 Dec; 35(12):798-799. PubMed ID: 35089002
[No Abstract] [Full Text] [Related]
4. Dynamic Treatment Stratification Using ctDNA.
Vidal J; Taus A; Montagut C
Recent Results Cancer Res; 2020; 215():263-273. PubMed ID: 31605234
[TBL] [Abstract][Full Text] [Related]
5. Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directions.
Cheng ML; Pectasides E; Hanna GJ; Parsons HA; Choudhury AD; Oxnard GR
CA Cancer J Clin; 2021 Mar; 71(2):176-190. PubMed ID: 33165928
[TBL] [Abstract][Full Text] [Related]
6. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
[TBL] [Abstract][Full Text] [Related]
7. Cell-Free DNA in the Liquid Biopsy Context: Role and Differences Between ctDNA and CTC Marker in Cancer Management.
Fici P
Methods Mol Biol; 2019; 1909():47-73. PubMed ID: 30580422
[TBL] [Abstract][Full Text] [Related]
8. Clinical implementation and current advancement of blood liquid biopsy in cancer.
Watanabe K; Nakamura Y; Low SK
J Hum Genet; 2021 Sep; 66(9):909-926. PubMed ID: 34088974
[TBL] [Abstract][Full Text] [Related]
9. Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
Wyatt AW; Annala M; Aggarwal R; Beja K; Feng F; Youngren J; Foye A; Lloyd P; Nykter M; Beer TM; Alumkal JJ; Thomas GV; Reiter RE; Rettig MB; Evans CP; Gao AC; Chi KN; Small EJ; Gleave ME
J Natl Cancer Inst; 2017 Dec; 109(12):. PubMed ID: 29206995
[TBL] [Abstract][Full Text] [Related]
10. Liquid biopsy and its role in an advanced clinical trial for lung cancer.
Johann DJ; Steliga M; Shin IJ; Yoon D; Arnaoutakis K; Hutchins L; Liu M; Liem J; Walker K; Pereira A; Yang M; Jeffus SK; Peterson E; Xu J
Exp Biol Med (Maywood); 2018 Feb; 243(3):262-271. PubMed ID: 29405770
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy in ovarian cancer using circulating tumor DNA and cells: Ready for prime time?
Asante DB; Calapre L; Ziman M; Meniawy TM; Gray ES
Cancer Lett; 2020 Jan; 468():59-71. PubMed ID: 31610267
[TBL] [Abstract][Full Text] [Related]
12. How liquid biopsies can change clinical practice in oncology.
Siravegna G; Mussolin B; Venesio T; Marsoni S; Seoane J; Dive C; Papadopoulos N; Kopetz S; Corcoran RB; Siu LL; Bardelli A
Ann Oncol; 2019 Oct; 30(10):1580-1590. PubMed ID: 31373349
[TBL] [Abstract][Full Text] [Related]
13. Parallel Evaluation of Circulating Tumor DNA and Circulating Tumor Cells in Metastatic Colorectal Cancer.
Germano G; Mauri G; Siravegna G; Dive C; Pierce J; Di Nicolantonio F; D'Incalci M; Bardelli A; Siena S; Sartore-Bianchi A
Clin Colorectal Cancer; 2018 Mar; 17(1):80-83. PubMed ID: 29195807
[TBL] [Abstract][Full Text] [Related]
14. Modeling clonal structure over narrow time frames via circulating tumor DNA in metastatic breast cancer.
Weber ZT; Collier KA; Tallman D; Forman J; Shukla S; Asad S; Rhoades J; Freeman S; Parsons HA; Williams NO; Barroso-Sousa R; Stover EH; Mahdi H; Cibulskis C; Lennon NJ; Ha G; Adalsteinsson VA; Tolaney SM; Stover DG
Genome Med; 2021 May; 13(1):89. PubMed ID: 34016182
[TBL] [Abstract][Full Text] [Related]
15. Liquid Biopsy: Approaches to Dynamic Genotyping in Cancer.
von Bubnoff N
Oncol Res Treat; 2017; 40(7-8):409-416. PubMed ID: 28693026
[TBL] [Abstract][Full Text] [Related]
16. Significance of postoperative follow-up of patients with metastatic colorectal cancer using circulating tumor DNA.
Benešová L; Hálková T; Ptáčková R; Semyakina A; Menclová K; Pudil J; Ryska M; Levý M; Šimša J; Pazdírek F; Hoch J; Blaha M; Minárik M
World J Gastroenterol; 2019 Dec; 25(48):6939-6948. PubMed ID: 31908397
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?
Cherng HJ; Herrera A
Curr Treat Options Oncol; 2024 May; 25(5):659-678. PubMed ID: 38656685
[TBL] [Abstract][Full Text] [Related]
18. Circulating tumor DNA (ctDNA) is not a good proxy for liquid biopsies of tumor tissues for early detection.
Fiala C; Diamandis EP
Clin Chem Lab Med; 2020 Sep; 58(10):1651-1653. PubMed ID: 32160156
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnology Strategies for the Analysis of Circulating Tumor DNA: A Review.
Chen X; Wang L; Lou J
Med Sci Monit; 2020 Mar; 26():e921040. PubMed ID: 32200389
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumor DNA in liquid biopsy: Current diagnostic limitation.
Liu SC
World J Gastroenterol; 2024 Apr; 30(15):2175-2178. PubMed ID: 38681986
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
